Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BEA 2180 BR in Healthy Males
NCT02263976Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of bea 2180 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with clinically significant changes in vital signs, Number of subjects with clinically significant changes in laboratory parameters and 5 more. Started Aug 2003; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02263976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263976.